Description

Who Should Take Semaglutide:

–Weight Loss: Semaglutide is suitable for patients with an initial BMI of 30 kg/m² or greater, or those with a BMI of 27 kg/m² or greater who have at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol). It is used alongside diet and exercise.
–Blood Sugar Control: Semaglutide is beneficial for type 2 diabetic patients to lower blood sugar levels.
–Cardiovascular Risk Reduction: It also helps reduce the risk of major cardiovascular events in type 2 diabetes patients with existing cardiovascular disease.

Notify your provider immediately if you notice a lump or swelling in your neck, hoarseness, difficulty swallowing, or shortness of breath. These could be symptoms of thyroid cancer.

Semaglutide is contraindicated if you or any of your family members have ever had medullary thyroid carcinoma (MTC), or if you suffer from an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

The safety and efficacy of combining semaglutide with other weight loss products have not been established.

Sharing your complete medical history with your provider is crucial. Specifically, inform your provider if you have a history of: Type 1 or type 2 diabetes, Thyroid cancer, Pancreatitis, Kidney disease, Diabetic retinopathy, Depression, Suicidal thoughts or behavior

Who Should Avoid Taking Semaglutide:

– Type 1 Diabetes: Semaglutide is not suitable for individuals with type 1 diabetes.
– Allergic Reactions: If you are allergic to semaglutide or any of its components, avoid using it.
– Medullary Thyroid Carcinoma (MTC):Semaglutide should not be used in patients with a history of MTC or in those with a family history of MTC.
– Multiple Endocrine Neoplasia Syndrome Type 2 (MEN 2): Avoid semaglutide if you have MEN 2.

Possible Drug Interactions:

– Insulin and Insulin Secretagogues: Semaglutide may increase the risk of hypoglycemia when used with insulin or insulin secretagogues (such as sulfonylureas). Dose adjustments may be necessary.
– Oral Medications: Semaglutide may delay gastric emptying, potentially affecting the absorption of orally administered medications. Administer oral medications at least 1 hour before semaglutide.
– Warfarin: Semaglutide may enhance the effect of warfarin. Monitor INR (International Normalized Ratio) closely if used together.
– Other GLP-1 Receptor Agonists: Avoid concomitant use with other GLP-1 receptor agonists.

General Cautions:

– Pancreatitis: Semaglutide has been associated with pancreatitis. Discontinue if pancreatitis is suspected.
– Thyroid C-Cell Tumors: Monitor for signs of MTC. Discontinue if MTC is confirmed.
– Renal Impairment: Use with caution in patients with renal impairment.
– Hypersensitivity Reactions: Be vigilant for allergic reactions (e.g., rash, urticaria, angioedema).
– Dehydration: Semaglutide may increase the risk of dehydration. Ensure adequate fluid intake.

Remember to consult your healthcare provider before starting any medication, including Semaglutide, to ensure it’s appropriate for your specific medical conditions and any potential drug interactions. Always follow your doctor’s advice and report any unusual symptoms promptly.